Eastbio announced on the interactive platform that their current Chikungunya detection products, including antigen, antibody IgM/IgG, and nucleic acid reagents, are predominantly sold to Africa, South America, Southeast Asia, and South Asia. Looking ahead, the company intends to proactively expand its market reach to other regions, contingent upon the acquisition of necessary certifications.